ESC Professional Premium Access

A randomized, cross-over study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of milvexian with single and dual antiplatelet therapy in healthy participants

Congress Session

About the speaker

Doctor Grigor Abelian

(United States of America)
2 followers

6 more presentations in this session

Effect of low-dose rivaroxaban with low-dose aspirin vs low-dose aspirin on platelet and oxidative biomarkers: a randomized study in diabetes patients with stable peripheral or coronary artery disease

Speaker: Associate Professor B. Rocca (Rome, IT)

Thumbnail

Antithrombotic strategies in antiphospholipid syndrome with arterial thrombosis: a systematic review and network meta-analysis

Speaker: Doctor T. Attachaipanich (Chiang Mai, TH)

Thumbnail

Combined anticoagulant and antiplatelet therapy is associated with an improved outcome in hospitalised patients with COVID-19: a propensity matched cohort study

Speaker: Doctor K. Matli (Beirut, LB)

Thumbnail

CS014 is a novel HDAC inhibitor regulating the platelet activity, fibrinolysis and clot stability for prevention of thrombosis without increased risk of bleeding

Speaker: Associate Professor M. Holinstat (Ann Arbor, US)

Thumbnail

Aspirin therapy on prophylactic anticoagulation for hospitalized patients with COVID-19: A propensity score-matched cohort analysis of the HOPE-COVID-19 registry.

Speaker: Doctor F. Santoro (Foggia, IT)

Thumbnail

Access the full session

Challenges and advances in antithrombotic therapy

Speakers: Doctor G. Abelian, Associate Professor B. Rocca, Doctor T. Attachaipanich, Doctor K. Matli, Associate Professor M. Holinstat...
Thumbnail

About the event

Image

ESC Congress 2022

26 August - 29 August 2022

Sessions Presentations

This platform is supported by

logo Novo Nordisk